AI Summary
We reviewed 6 live results for bat2206 (ustekinumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Immunology and Pharmaceuticals.
Comparison Table
Recommended
BAT2206 (Ustekinumab)
Source: Dr. Reddy’s Laboratories
Description
BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis.
Best for
plaque psoriasis, psoriatic arthritis and autoimmune disease treatment
View Details
Rating
Stelara (ustekinumab)
Source: Janssen
Description
Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion.
Best for
pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management
View Details
Rating
Epyztek (ustekinumab)
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
patients in South Korea, psoriasis treatment and local biosimilar seekers
View Details
Rating
| Compare | BAT2206 (Ustekinumab) | Stelara (ustekinumab) | Epyztek (ustekinumab) |
|---|---|---|---|
| Source | Dr. Reddy’s Laboratories | Janssen | Samsung Bioepis |
| Description | BAT2206 is a biosimilar candidate for Ustekinumab, targeting autoimmune conditions like plaque psoriasis and psoriatic arthritis. | Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion. | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. |
| Best for | plaque psoriasis, psoriatic arthritis and autoimmune disease treatment | pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management | patients in South Korea, psoriasis treatment and local biosimilar seekers |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"BAT2206 (Ustekinumab) from Dr. Reddy’s Laboratories."
I picked this because This biosimilar represents the latest advancements in autoimmune treatments coming to the Philippine market in 2025.
Share this search
Related Finds